Dr Miller has worked for over 25 years in the bioscience industry,
with extensive experience in commercial drug development.
She completed her PhD in the Faculty of Medicine at Sydney University investigating molecular models of cancer development.
Her experience includes several years at Johnson and Johnson developing anti-HIV gene therapeutics through preclinical research to clinical trials.
She has finance industry experience from time spent as an Investment Manager with a specialist bioscience venture capital fund.
Michelle Initiated the program to develop 250 potential new drugs,
Which has now risen to over 350 compounds.
BIT 225 was one of them.
Without Michelle BIT as we know it might well not exist.
"Miller came on board, “intrigued” by Gage’s novel approach,
but her big pharma experience soon told her they needed to develop a new drug,
to maximise the commercial potential.
Gage’s compounds were known compounds that Biotron had ‘use patents’ for – types of patents that give a company the right to use someone else’s compound in a particular way – and they weren’t human-approved drugs.
What Biotron needed was a ‘composition of matter’ patent on a drug that stopped the VPU protein’s ion channels from working in HIV.
They needed to own a molecule. “If you design a drug, you make it, and nobody else has made it before and described it, and you can show what it does – you own it for 20 years,” says Miller.
So Miller initiated a program to develop about 250 potential new drugs that were related to, but not the same as, Gage’s compounds and then set about selecting the best one to progress."
"The compound they eventually picked, called BIT225, is currently undergoing phase II clinical trials"
BIT Price at posting:
7.1¢ Sentiment: Buy Disclosure: Held
